Development of a new allogeneic hematopoietic stem cell transplantation method with co-thymus transplantation from the same donor —mechanism and application for intractable diseases—
-
- HOSAKA Naoki
- Department of Pathology, Kansai Medical University-Kori Hospital Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University
Bibliographic Information
- Other Title
-
- 胸腺移植併用による新しいアロ造血幹細胞移植法の開発－その機構と難治性疾患への応用－
Search this article
Description
Allogeneic Hematopoietic stem cell transplantation (allo-HSCT) is effective for several diseases, including leukemia, solid tumors, and immunodeficiency. However, there are still some intractable diseases that cannot be treated with HSCT alone. We have developed a new HSCT method, allo-HSCT + thymus transplantation (TT) from the same donor, which induces elevated T cell function with mild graft-versus-host disease (GVHD) in comparison to conventional HSCT alone and HSCT + donor lymphocyte infusion (HSCT + DLI). This method leads to improvement of immune function and the ability of engraftment, and is effective for treatment of autoimmune chronic pancreatitis and sialoadenitis in aging, lupus nephritis in hosts with radioresistance, and supralethal irradiation, in which conventional HSCT alone is ineffective. This method may become a valuable form of clinical therapy for intractable diseases.
Journal
-
- Japanese Journal of Clinical Immunology
-
Japanese Journal of Clinical Immunology 37 (1), 42-47, 2014
The Japan Society for Clinical Immunology
